News - Astellas Pharma, Xtandi

Filter

Current filters:

Astellas PharmaXtandi

Popular Filters

1 to 25 of 31 results

Astellas details pipeline progress at R&D meeting

Astellas details pipeline progress at R&D meeting

11-07-2014

Japanese drug major Astellas Pharmaceuticals outlined its research framework at its R&D meeting held…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesAstellas PharmaBetmigaisavuconazoleJapanNephrology and HepatologyOncologyPharmaceuticalroxadustatXtandi

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

NICE issues positive recommendation for Astellas' Xtandi

NICE issues positive recommendation for Astellas' Xtandi

09-05-2014

In an about turn, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has…

Astellas PharmaOncologyPharmaceuticalPricingRegulationUKXtandi

US priority review for Astellas and Medivation’s sNDA for prostate cancer

US priority review for Astellas and Medivation’s sNDA for prostate cancer

06-05-2014

Japanese drug major Astellas' US subsidiary and Medivation revealed that the US Food and Drug Administration…

Astellas PharmaBiotechnologyMedivationOncologyRegulationUSAXtandi

Promising emerging agents for triple negative breast cancer

08-04-2014

Due to the heterogeneity of triple negative breast cancer, the most promising emerging agents in development…

Astellas PharmaBiotechnologyMarkets & MarketingMedivationniraparibOncologyTesaroXtandi

Astellas files for wider use of prostate cancer drug Xtandi in Europe

03-04-2014

Japanese drug major Astellas Pharma has submitted a variation to amend the Marketing Authorization Application…

Astellas PharmaEuropeMedivationOncologyPharmaceuticalRegulationXtandi

Astellas’ Xtandi cleared in Japan for prostate cancer treatment

24-03-2014

Japanese drug major Astellas Pharma has obtained the marketing approval in Japan of its oral androgen…

Asia-PacificAstellas PharmaJapanMedivationOncologyPharmaceuticalRegulationXtandi

Astellas and Medivation file sNDA for new Xtandi indication

Astellas and Medivation file sNDA for new Xtandi indication

18-03-2014

Japanese drug major Astellas Pharma and US partner Medivation have filed a supplemental New Drug Application…

Astellas PharmaMedivationNorth AmericaOncologyPharmaceuticalRegulationUSAXtandi

IQWiG now finds “major” benefit for Xtandi

24-02-2014

In an early benefit assessment under Germany’s Act on the Reform of the Market for Medicinal Products…

Astellas PharmaGermanyMedivationNorthern EuropeOncologyPharmaceuticalPricingRegulationXtandi

Medivation and Astellas announce final results of Phase III enzalutamide trial in prostate cancer

Medivation and Astellas announce final results of Phase III enzalutamide trial in prostate cancer

29-01-2014

Medivation and Japanese drug major Astellas Pharma have announced final results on the primary and secondary…

Astellas PharmaenzalutamideMedivationOncologyPharmaceuticalResearchUSAXtandi

Latest guidance from UK’s NICE on Xtandi disappoints Astellas

Latest guidance from UK’s NICE on Xtandi disappoints Astellas

28-01-2014

UK drugs watchdog the National Institute of Health and Care Excellence (NICE) has issued new draft guidance…

Astellas PharmaEuropeOncologyPharmaceuticalPricingRegulationUKXtandi

IQWiG finds hint of added benefit for Xtandi in prostate cancer

IQWiG finds hint of added benefit for Xtandi in prostate cancer

09-12-2013

In an early benefit assessment under the Act on the German Reform of the Market for Medicinal Products…

Astellas PharmaEuropeMedivationOncologyPharmaceuticalPricingRegulationXtandi

Prostate cancer market to almost double to $8 billion by 2019, says GBI

21-11-2013

The prostate cancer treatment market is forecast to increase from $4.1 billion in 2012 to $8 billion…

Active BiotechAstellas PharmaJohnson & JohnsonMarkets & MarketingOncoGenexOncologyPharmaceuticalTeva Pharmaceutical IndustriesXofigoXtandiZytiga

Regulator backs Inlyta, Lucentis and Xtandi for NHS Scotland, but not Bosulif

12-11-2013

The Scottish Medicines Consortium (SMC) revealed this morning (November 12) that it has accepted US drug…

Astellas PharmaBosulifEuropeInlytaLucentisNovartisOncologyOphthalmicsPfizerPharmaceuticalRegulationXtandi

Medivation and Astellas reveal positive Phase III results for prostate cancer drug

Medivation and Astellas reveal positive Phase III results for prostate cancer drug

23-10-2013

Medivation and Japanese drug major Astellas Pharma have announced positive results from the Phase III…

Asia-PacificAstellas PharmaenzalutamideMedivationOncologyPharmaceuticalResearchXtandi

UK’s NICE approves Astellas Pharma’s new prostate cancer drug

UK’s NICE approves Astellas Pharma’s new prostate cancer drug

18-10-2013

NICE has issued new draft guidance recommending Xtandi from Astellas Pharma as an option for treating…

Astellas PharmaEuropeOncologyPharmaceuticalRegulationXtandi

Prostate cancer market set to grow 50% by 2021: report

06-09-2013

The increasing number of sufferers and the uptake of new drugs will see the prostate cancer market grow…

Asia-PacificAstellas PharmaEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalXtandiZytiga

Astellas and Medivation's Xtandi approved in EU for advanced prostate cancer

24-06-2013

Japanese drug major Astellas Pharma (TYO: 4503) European subsidiary today (June 24) received approval…

Astellas PharmaEuropeMedivationOncologyPharmaceuticalRegulationXtandi

Astellas and Medivation file for approval of enzalutamide in Japan

24-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) has submitted an application for marketing approval of…

Asia-PacificAstellas PharmaenzalutamideMedivationOncologyPharmaceuticalRegulationXtandi

Six months post launch, US prescribing trends for Xtandi

07-05-2013

At six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists…

3MAstellas PharmaJevtanaJohnson & JohnsonMarkets & MarketingMedivationNorth AmericaOncologyPharmaceuticalSanofiXtandiZytiga

BioTrends views Xeljanz and Zytiga prescribing in USA

26-03-2013

After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

New drug options for advanced prostate cancer

13-12-2012

Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

1 to 25 of 31 results

Back to top